x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243328
| Product Information | |
|---|---|
| CAS No. | 2360487-93-8 |
| Formula | C30H34F3N7O4S |
| Molecular Weight | 645.70 |
| SMILES | O=C(N(C1CCC2(C1)CN(C2)C3=C4C=C(CC(F)(F)F)SC4=NC=N3)CC5=CC=C6C(NC(N6CC(N)=O)=O)=C5)OC(C)(C)C |
| Target | Epigenetic Reader Domain |
| Product Description | Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of menin-mll interaction, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseaech of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | White to light yellow |
| Purity | 98.07% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
